Rapcabtagene autoleucel is named as a drug or biological intervention in 4 clinical trials in our UK and USA trial registers, none of which are currently recruiting. The lead sponsor is Novartis Pharmaceuticals. Registered phase: Phase 2. Conditions studied include ANCA Associated Vasculitis (AAV); Scleroderma, Diffuse; Idiopathic Inflammatory Myopathies.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) (ClinicalTrials.gov ↗) Lupus Erythematosus, Systemic, Lupus Nephritis |
Phase 2 | Active, closed |
| NCT06655896 | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis (ClinicalTrials.gov ↗) Scleroderma, Diffuse |
Phase 2 | Active, closed |
| NCT06665256 | Phase 2 Study of Rapcabtagene Autoleucel in Myositis (ClinicalTrials.gov ↗) Idiopathic Inflammatory Myopathies |
Phase 2 | Active, closed |
| NCT06868290 | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA (ClinicalTrials.gov ↗) ANCA Associated Vasculitis (AAV) |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| ANCA Associated Vasculitis (AAV) | 1 |
| Scleroderma, Diffuse | 1 |
| Idiopathic Inflammatory Myopathies | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lupus Nephritis | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Register | Rapcabtagene autoleucel trials |
|---|---|
| Clinical trials in UK | 4 |
| Clinical trials in USA | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rapcabtagene autoleucel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rapcabtagene autoleucel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.